BRIEF-Quantum Biopharma Submits Investigational New Drug (Ind) Application To United States Food And Drug Administration (FDA)

Quantum Biopharma Ltd. Subordinate Voting Shares Class B

Quantum Biopharma Ltd. Subordinate Voting Shares Class B

QNTM

0.00

April 1 (Reuters) - Quantum Biopharma Ltd QNTM.CD:

  • QUANTUM BIOPHARMA SUBMITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) FOR LUCID-MS PHASE TWO CLINICAL TRIAL IN MULTIPLE SCLEROSIS

  • QUANTUM BIOPHARMA LTD - ANTICIPATED FDA RESPONSE TO IND SUBMISSION IN Q2 2026

  • QUANTUM BIOPHARMA LTD - PHASE 2 TRIAL INITIATION FOR LUCID-MS PLANNED FOR Q2 2026

  • QUANTUM BIOPHARMA LTD - PHASE 2 INTERIM DATA FOR LUCID-MS PROJECTED FOR Q4 2026

Source text: ID:nGNX8qDM0X

Further company coverage: QNTM.CD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.